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• Reclassify T2aN1 tumours (≤5 cm) as stage IIA (from IIB). 
• Reclassify T2bN0 tumours (>5-7 cm) as stage IIA (from IB). 
• Reclassify T4N0 and T4N1 tumours as stage IIIA (from IIIB). 
The resultant TNM stage groupings are summarised as: 
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a, b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a, b N1 M0
T2a N1 M0
T2b N0 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1, T2 N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1a,b
The table below summarises the descriptors, proposed T and M catego-
ries, and proposed stage groupings. Shaded cells indicate a proposed 
change from the 6th Edition of the TNM Classiﬁcation for lung cancer 
for a particular TNM category.
UICC6 T/M and 
Descriptor
Proposed 
T/M
N0 N1 N2 N3
T1 (<=2cm) T1a IA IIA IIIA IIIB
T1 (>2 – 3 cm) T1b IA IIA IIIA IIIB
T2(<=5cm) T2a IB IIA IIIA IIIB
T2 (>5-7cm) T2b IIA IIB IIIA IIIB
T2 (>7cm) T3 IIB IIIA IIIA IIIB
T3 invasion IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung) IIIA IIIA IIIB IIIB
T4 (pleural eﬀusion) M1a IV IV IV IV
M1 (contralateral lung) IV IV IV IV
M1 (distant) M1b IV IV IV IV
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Current staging methods are inadequate for predicting outcome of 
treatment of lung cancer. Although, the need for better staging systems 
seems more relevant for early stage disease, improvements in treatment 
results also for advanced disease calls for a better staging/prognostic 
system.
The ability to deﬁne cancer subtypes, recurrence of disease and re-
sponse to speciﬁc therapies using DNA microarray-based gene expres-
sion signatures has been demonstrated in multiple studies (1) 
1. Early Stage NSCLC; Within the last years emerging data has justi-
ﬁed adjuvant therapy for subsets of early stage disease. Clinical studies 
have not yet justiﬁed the role of adjuvant therapy for stage IA. How-
ever, still about 25% of the NSCLC patients in stage IA will later have 
disease recurrence, which emphasize the importance of a better staging 
system. More recently several studies based on molecular markers have 
been published indicating the possibility of a more reﬁned classiﬁca-
tion of NSCLC patients with different outcome after surgery. In a study 
high risk stage I lung adenocarcinomas of Beer et al (2), it was possible 
to make a gene-risk proﬁling based on oligonucleotide array deﬁn-
ing clusters of genes with good and poor outcome. A kind of similar 
approach was taken by Potti et al. (3) in the lung metagene model. The 
lung metagene model predictited recurrence for individual patients 
signiﬁcantly better than did clinical prognostic factors and was con-
sistent across all early stages of NSCLC.The predictor also identiﬁed 
a subgroup of patients with stage IA disease who were at high risk for 
recurrence and who might be best treated with adjuvant chemotherapy. 
The metagene predictor is currently validated in a prospective CALGB 
study. Bild et al.(4) demonstrated that by identifying patterns of several 
pathway deregulation by using hierarchical clustering, it is possible to 
identify populations of patients with different prognosis. Independent 
of tumor histopathology concerted deregulation of Ras with β-catenin, 
Src and myc identiﬁed a group of lung cancer patients with poor sur-
vival with a median survival of 19.7 months versus 51.3 months for all 
other clusters (4). This analysis demonstrated the ability of integrated 
pathway analysis, based on multiple signatures of component pathway 
deregulation, to deﬁne improved categorization of lung cancer patients.
Other studies have used PCR based analysis in order to ﬁnd a better 
molecular prognostic signature. In a study from Taiwan a ﬁve-gene 
signature identiﬁed from 125 randomly selected patients who had 
undergone surgical resection of NSCLC, and the model were validated 
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in an independent cohort demonstrating close association with relapse-
free and overall survival (5). 
Future comparative studies need to deﬁne “common” signatures from 
the different studies, which might optimize the gene prognostic models 
for early stage NSCLC.
DNA Synthesis and Repair genes (i. e RRM1 and ERCC1) have been 
associated with sensitivity to certain chemotherapeutica (gemcitabine/
cisplatinum). The prognostic value of these markers have also been 
studied by a new immunohistochemistry/ﬂuorescence technique (the 
AQUA-system), which demonstrated a strong association to survival 
after surgery for patients between high expression of RRM1 and 
ERCC1, especially for the 30% of the patients with tumors express-
ing both markers. As a single marker patients with high expression of 
RRM1 had an overall survival of 120 months versus 60 months for the 
patients with low expression (HR for death was 0.61, p=0.02). (6).
2. Advanced Disease: In the advanced disease situation the prognos-
tic information is more related to prediction of sensitivity to any give 
systemic therapy. Within the last years much progress has been done in 
this area, both with regard to new targeted therapies as well as conven-
tional chemotherapy.
Epidermal Growth Factor Tyrosine Kinase Inhibitors (EGFR TKIs) 
have demonstrated signiﬁcant effect in a subset of patients with ad-
vanced NSCLC. The identiﬁcation of certain EGFR mutations role for 
sensitivity to these agents was a signiﬁcant discovery and focused the 
future research in this ﬁeld (8). EGFR mutations in the tyrosine kinase 
domain, especially in exons 19 and 21 play a role for response to EGFR 
TKIs and several reports points to the fact that EGFR mutations in exon 
19 are more related to sensitivity than exon 21 mutations, which also 
seems to have a prognostic association (9). While the EGFR mutations 
in Asian populations seems to be clearly associated to survival as well, 
more clinical data seems to be needed to verify the same for the west-
ern populations. More consistent association to response and survival 
has been published for increased EGFR gene copy number detected by 
FISH (10, 11). While the routine use of tissue based predictive markers 
could have some limitations in terms of tissue acquisition and tumor 
heterogeneity, the identiﬁcation of blood- based predictive markers 
could be advantageous. Most recently, a serum proteomic proﬁling was 
identiﬁed, which could distinguish NSCLC patients with good and poor 
outcome after EGFR TKIs (12).
While other targeted therapies have emerged promising in the treatment 
of advanced NSCLC, no validated predictive molecular signatures have 
so far been identiﬁed, which could immediately be ready for routine 
clinical management.
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Appropriate management of (N)SCLC depends on precise disease 
staging and accurate response assessment. Currently, the tumor-node-
metastases (TMN) staging is used in most parts of the world. The 1997 
staging system adopted by the AJCC and UICC is currently undergoing 
revision as a result of the IASLC staging effort. 
In the recent years, common imaging modalities used for staging lung 
cancer patients include chest radiography, CT, magnetic resonance 
imaging, (FDG)PET and fused modality imaging (PET-CT). Whereas 
chest CT is useful in identifying tumor location and the presence of 
mediastinal lymph node involvement, its limitation is the ability to 
differentiate between benign and malignant pulmonary nodules and 
lymph nodes. FDG-PET as a single imaging modality has shown to be 
superior to conventional imaging in direct comparisons with respect 
to differentiate between benign and malignant pulmonary nodules, 
mediastinal lymph node metastases and distant metastatic disease (with 
the noteworthy exception of brain metastases). Although recent reports 
indicate that the accuracy of staging of integrated PET-CT is superior 
to either CT alone and dedicated PET that was visually correlated 
with a CT scan, the true cost-effectiveness of this staging modality 
is unknown. One drawback of FDG-PET is that it still lacks absolute 
speciﬁcity for differentiating benign (eg inﬂammation) from malignant 
disease. For this reason, tissue sampling of “decisive” lesions (eg those 
that will determine stage) is still mandatory. For suspect mediastinal de-
posits the procedure of choice has long been invasive surgical staging: 
depending on their localization either mediastinoscopy, mediastinoto-
my anterior or less frequently VATS. The advent of ultra sound (US) 
-guided endoscopes, through which ﬁne needle aspiration is possible, is 
now changing the diagnostic algorithm. Endobronchial US-guided ﬁne 
needle aspiration (EBUS) can be performed during ﬁberoptic bronchos-
copy, and a prior (PET-)CT allows nodes to be targeted and sampled, 
mainly in the same areas accessible to cervical mediastinoscopy, with 
the addition of some hilar nodes. Esophageal endoscopic ultrasound 
(EUS) allows examination of the posterior and inferior mediastinum 
and far more-the liver, the celiac axis, and the left adrenal gland. In 
